2026-04-17T17:52:47Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4852112025-09-17T08:28:59Zcom_2072_98col_2072_378192

Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab : A Multicenter Retrospective Study in Spain Magdaleno-Tapial, Jorge Ortiz-Salvador, José María Sánchez-Carazo, José Luis Hernández-Bel, Pablo Pérez-Ferriols, Amparo Santos-Alarcón, Sergio Sahuquillo-Torralba, Antonio Pujol-Marco, Conrad Rivera-Díaz, Raquel Belinchón-Romero, Isabel Ruiz-Geneao, Diana Romero-Maté, Alberto Ruíz Villaverde, Ricardo Ferran, Marta Gallardo, Fernando Almenara-Blasco, Manuel Alonso-Suárez, Jorge González-Cantero, Álvaro Martínez-Lorenzo, Elena Fernández-Armenteros, José Manuel De Alcázar-Viladomiu, Elena García-Latasa, Javier Rocamora-Durant, Vicenç Ara-Martín, Mariano Mateu-Puchades, Almudena Llamas-Velasco, Mar Vilarrasa-Rull, Eva Velasco-Pastor, Manuel De La Cueva-Dobao, Pablo Carrascosa, José Manuel Martorell-Calatayud, Antonio Background. Current psoriasis treatment goals emphasize achieving complete or near-complete skin clearance while preserving the quality of life, necessitating treatment modification for a suboptimal or inadequate response. Despite risankizumab's demonstrated efficacy, evidence remains limited for patients switching from ustekinumab, particularly those with suboptimal or inadequate response. Objective. This study assesses risankizumab's real-world effectiveness in patients with suboptimal response (PASI 2-3), inadequate response (PASI 3-5), or failure (PASI >5) to ustekinumab, based on a multicenter retrospective cohort in Spain. Method. A multicenter retrospective study across 24 Spanish hospitals included 102 patients previously treated with ustekinumab and switched to risankizumab. Results. Out of 102 patients, 78 experienced ustekinumab treatment failure (PASI >5), while 24 had an inadequate response (PASI 3-5), including 6 with a suboptimal response (PASI 2-3). Remarkably, after one year of treatment with risankizumab, all patients demonstrated improvement, achieving near-complete or complete skin clearance (PASI 0-1). Conclusion. Risankizumab displayed effectiveness in patients with suboptimal/inadequate response or treatment failure to ustekinumab, aligning with the current treatment goals of complete or near-complete skin clearance. These real-world results corroborate clinical trial data, emphasizing risankizumab's potential as a powerful therapeutic alternative for this patient population. Further prospective studies are essential to validate these findings. 2024 Article https://ddd.uab.cat/record/311597 urn:10.1155/2024/5528484 urn:oai:ddd.uab.cat:311597 urn:scopus_id:85201152313 urn:oai:egreta.uab.cat:publications/c94738c3-9f36-42d1-b96f-b1c22f394fc7 eng Dermatologic therapy ; Vol. 2024, Núm. 1 (July 2024) open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/ application/pdf